Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAX | P61244 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29946149 | 1.00 | CASP6 (0.44) | CASP6MAPTMYCMAXTDP1 | |
| SCHEMBL29231882 | 0.87 | MYC (0.50) | MAPTMYCMAXL3MBTL1TSHR | |
| SCHEMBL27227118 | 0.86 | MAPT (0.41) | CASP6MAPTTDP1POLBL3MBTL1 | |
| SCHEMBL805290 | 0.84 | MAPT (0.41) | MAPTTDP1POLBL3MBTL1TSHR | |
| SCHEMBL11842583 | 0.82 | VCAM1 (0.52) | CASP6MAPTPOLBPIN1MAPK1 | |
| SCHEMBL30494022 | 0.82 | L3MBTL1 (0.50) | CASP6MAPTMYCMAXTDP1 | |
| SCHEMBL2255634 | 0.82 | L3MBTL1 (0.50) | CASP6MAPTMYCMAXTDP1 | |
| SCHEMBL16931203 | 0.81 | CASP6 (0.47) | CASP6MAPTMYCMAXTDP1 | |
| SCHEMBL30815577 | 0.80 | MYC (0.41) | MAPTMYCMAXPOLBL3MBTL1 | |
| SCHEMBL29556542 | 0.80 | MAPT (0.42) | MAPTMYCMAXTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4651907-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | Adcentrx Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| CN-119350323-B | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3288940-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176460-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| EP-2366691-B1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO LTD (CN) | 2015-04-15 | — | — | EP | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
| EP-2366691-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | Beijing Yiling Bioengineering Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | CASP6 3974/4885MAPT 2655/4885MYC 4589/4885 |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CASP6 2503/4885MAPT 3373/4885MYC 718/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | CASP6 356/4885MAPT 2491/4885MYC 2305/4885 |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | TP53, NPM1, TP53BP1 | CASP6 1774/4885MAPT 3898/4885MYC 59/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | CASP6 484/4885MAPT 4841/4885MYC 2878/4885 |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CASP6 2503/4885MAPT 3373/4885MYC 718/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | CASP6 426/4885MAPT 4842/4885MYC 2932/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | CASP6 484/4885MAPT 4841/4885MYC 2878/4885 |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 | CASP6 383/4885MAPT 4403/4885MYC 497/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | CASP6 3974/4885MAPT 2655/4885MYC 4589/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | CASP6 3862/4885MAPT 2649/4885MYC 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.